Life Sciences

  • January 12, 2026

    Terumo Plaintiff Settles, Drops Cancer Case Before Trial

    One of the two plaintiffs set to take their case to trial this month against Terumo BCT Inc. accusing the company of causing their cancer reached a stipulation to dismiss his case with prejudice Friday, according to court records.

  • January 12, 2026

    Del. Court Blocks Presuit Damages On Agilent Patent

    A Delaware federal court ruled that laboratory equipment company Agilent Technologies couldn't collect damages for any alleged infringement of one of its patents prior to the filing of its intellectual property lawsuit against biotechnology business Axion BioSystems.

  • January 12, 2026

    Feds To Drop Appeal In 340B Rebate Pilot Challenge

    The U.S. Department of Health and Human Services on Monday suggested it will end its appeal of a First Circuit order temporarily blocking it from instituting a rebate program that would change how the agency distributes payments in the federal 340B drug discount program that provides medications at reduced costs to low-income Americans. 

  • January 12, 2026

    Sidley-Led Smith & Nephew Inks $450M Orthopaedics Deal

    Sidley Austin-advised Smith & Nephew said Monday it will acquire Gunderson Dettmer-led U.S. sports medicine company Integrity Orthopaedics and its Tendon Seam rotator cuff repair technology in a deal valued at up to $450 million.

  • January 12, 2026

    Medicine Biz Mirador Wraps $250M Funding Round

    San Diego-based clinical-stage precision medicine company Mirador Therapeutics Inc. announced Monday that it closed its Series B funding round with $250 million of investor commitments, bringing the company's total capital raised since its March 2024 launch to more than $650 million.

  • January 12, 2026

    Justices Want SG Input On Arthritis Drug Competition Fight

    The U.S. Supreme Court on Monday asked the Trump administration to weigh in on whether state unfair competition claims should be used to block a competitor from selling compounded versions of drugs in certain states.

  • January 12, 2026

    No High Court Review For California Opioid 'Nuisance' Suit

    The U.S. Supreme Court on Monday said it would not weigh in on a circuit court decision that a California public nuisance lawsuit against pharmacy benefit managers over their opioid-dispensing practices belongs in state court.

  • January 12, 2026

    Justices Won't Weigh Collective Cert. Process In Eli Lilly Case

    The U.S. Supreme Court declined on Monday to review whether courts should stick with a long-standing two-step analysis for certifying collective actions in an age discrimination case against Eli Lilly and Co. that could have affected wage and hour litigation.

  • January 09, 2026

    Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims

    A Connecticut federal judge on Friday refused to hand a quick win to Mylan Pharmaceuticals and Aurobindo Pharma USA in sprawling antitrust litigation against 26 total pharmaceutical companies, ruling that a coalition of states has enough evidence to raise a genuine dispute about whether the companies conspired to fix drug prices.

  • January 09, 2026

    Squires Sets Precedent, Guidance On Discretionary Denials

    U.S. Patent and Trademark Office Director John Squires on Friday designated four decisions on discretionary denials at the Patent Trial and Appeal Board precedential and another nine informative.

  • January 09, 2026

    Biopharma Co. Secures D&O Coverage For Shareholder Suit

    A biopharmaceutical company is entitled to coverage for a suit alleging its board breached fiduciary duties under a pair of primary and excess directors and officers policies, a Delaware state court ruled, saying the suit is "meaningfully linked" to a previously noticed demand for books and records.

  • January 09, 2026

    Veterinary Group Says DOJ Accreditation Points Irrelevant

    The American Veterinary Medical Association has told a Tennessee federal court that the government's concerns about professional groups are irrelevant to a veterinary school's antitrust case challenging the association's accreditation requirements.

  • January 09, 2026

    Judge Denies 'Fatally Untimely' Bid For New Poaching Trial

    A Boston federal judge has denied what she called a "fatally untimely" motion for a new trial after a jury handed Cynosure LLC a $25 million verdict against two former employees who the company said caused other employees to breach their noncompete and nonsolicitation agreements.

  • January 09, 2026

    Judge Blocks Edwards' $945M Heart Valve Deal

    A D.C. federal judge issued an order on Friday preventing Edwards Lifesciences Corp. from moving ahead with its planned $945 million deal for JenaValve Technology Inc., torpedoing the merger challenged by the Federal Trade Commission.

  • January 09, 2026

    4 Argument Sessions That Benefits Attys Should Watch In Jan.

    The U.S. Supreme Court will zero in on the methodology for assessing liability for pulling out of a multi-employer pension fund, and the circuit courts will hear bids to revive suits over alleged 401(k) mismanagement and deferred compensation. Here, Law360 looks at a quartet of oral arguments coming up in January.

  • January 09, 2026

    How New Judges Can Quell Patent Litigation Fears

    Patent litigation has a reputation for being particularly complex due to its technical content, which can be intimidating for litigants, attorneys and judges alike. In the first of a two-part series, several judges in the trenches of patent law spoke with Law360 about how new judges can make patent litigation less overwhelming.

  • January 09, 2026

    Ex-Prosecutor OK For Drug Pricing MDL, Special Master Says

    Former Connecticut Assistant Attorney General Joseph Nielsen and his law firm, Lowey Dannenberg PC, should not be disqualified from representing insurers in multidistrict litigation over generic drug price-fixing because he did not have any special knowledge that the states suing drugmakers hadn't already shared with the private plaintiffs, according to a special master's report and recommendation.

  • January 09, 2026

    Biotech AirNexis Wraps Funding Round With $200M Raised

    Clinical stage biotech firm AirNexis, advised by Fenwick & West LLP, on Friday announced that it wrapped its Series A funding round with $200 million in tow, which will be used to fund the global clinical development of a therapy used for chronic obstructive pulmonary disease.

  • January 09, 2026

    NC Biz Court Bulletin: Trade Secrets Row, A Patient Data Deal

    The North Carolina Business Court closed out the year by tossing a trade secrets fight brought by a corrugated packing manufacturer against its onetime star salesman and signing off on a $2.45 million settlement ending claims a healthcare system sold patients' data to Meta.

  • January 09, 2026

    IDEXX Software Defect Blamed For At Least 40 Dog Deaths

    Two Los Angeles-based veterinary clinics say pet healthcare diagnostics company Idexx Distribution Inc. fraudulently concealed a software algorithm defect that allegedly led to at least 40 dogs dying and hundreds of animals getting sick or missing treatment due to false diagnostic testing, according to a new lawsuit in California state court.

  • January 09, 2026

    Paul Hastings-Led Oncology Firm Prices Upsized $318M IPO

    Boston-based biotech firm Atkis Oncology began trading publicly Friday after raising roughly $318.6 million in its upsized initial public offering, marking the first sizable IPO of 2026.

  • January 08, 2026

    Walgreens Gets $392K Sanction Against Blue Cross Insurers

    A Chicago federal judge on Thursday ordered a host of Blue Cross Blue Shield insurers to pay Walgreens more than $392,000 in attorney fees and expenses for discovery misconduct in their suit that accuses the drugstore company of fraudulently overcharging for prescription drugs.

  • January 08, 2026

    Apple Beats Antitrust Suit Over Heart Rate Data At 9th Circ.

    A Ninth Circuit panel affirmed Apple's win Thursday against startup AliveCor Inc.'s antitrust claims alleging it illegally blocked third-party access to Apple Watch medical data to create rival software, finding that Apple has no "duty to deal" with AliveCor and therefore the startup's claims fail as a matter of law.

  • January 08, 2026

    FTC Battles Edwards On Eve Of Heart Valve Merger Deadline

    The Federal Trade Commission asked a D.C. federal judge for a last-minute extension on an order blocking Edwards Lifesciences' $945 million acquisition of JenaValve Technology Inc., fearing difficulty with unscrambling the egg if the block expires Friday, the judge rejects its merger challenge and the deal closes before the agency can appeal.

  • January 08, 2026

    AbbVie Sues Over Bids To Market Generic Migraine Drugs

    AbbVie and its Allergan unit have filed patent infringement lawsuits against MSN Pharmaceuticals and Hetero in New Jersey federal court, alleging the two pharmaceutical companies are infringing on patents for the migraine drug Qulipta.

Expert Analysis

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Where 4th And 9th Circ. Diverge On Trade Secret Timing

    Author Photo

    Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

  • Courts Are Still Grappling With McDonnell, 9 Years Later

    Author Photo

    The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.

  • AI Will Transform Patent Examination For The Better

    Author Photo

    The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.

  • Hybrid Claims In Antitrust Disputes Spark Coverage Battles

    Author Photo

    Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.

  • Drug Ad Crackdown Demonstrates Admin's Aggressive Stance

    Author Photo

    Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.

  • Protecting Sensitive Court Filings After Recent Cyber Breach

    Author Photo

    In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.

  • Series

    Judging Figure Skating Makes Me A Better Lawyer

    Author Photo

    Judging figure skating competitions helps me hone the focus, decisiveness and ability to process complex real-time information I need in court, but more importantly, it makes me reengage with a community and my identity outside of law, which, paradoxically, always brings me back to work feeling restored, says Megan Raymond at Groombridge Wu.

  • Trending At The PTAB: Petitioners' Settled Expectations

    Author Photo

    Recent Patent Trial and Appeal Board decisions show that the U.S. Patent and Trademark Office's new "settled expectations" factor is no longer the exclusive domain of patent owners and can also provide petitioners with viable pathways to argue against discretionary denial, say attorneys at Finnegan.

  • 9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims

    Author Photo

    The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.